EA200101125A1 - Способ понижающей регуляции активности il5 - Google Patents

Способ понижающей регуляции активности il5

Info

Publication number
EA200101125A1
EA200101125A1 EA200101125A EA200101125A EA200101125A1 EA 200101125 A1 EA200101125 A1 EA 200101125A1 EA 200101125 A EA200101125 A EA 200101125A EA 200101125 A EA200101125 A EA 200101125A EA 200101125 A1 EA200101125 A1 EA 200101125A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modified
well
analogs
nucleic acid
production
Prior art date
Application number
EA200101125A
Other languages
English (en)
Inventor
Стеен Клюснер
Original Assignee
Фармекса А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармекса А/С filed Critical Фармекса А/С
Publication of EA200101125A1 publication Critical patent/EA200101125A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Данное изобретение относится к усовершенствованиям при лечении и профилактике состояний, характеризующихся повышенным уровнем эозинофильных лейкоцитов, а именно таких состояний, как астма и другие хронические аллергические болезни. Предоставляется способ понижающей регуляции интерлейкина 5 (IL5) путем обеспечения возможности продукции антител против IL5, тем самым снижая уровень активности эозинофилов. Изобретение также предоставляет способы получения модифицированного IL5, пригодного для данного способа, а также модифицированного IL5, как такового. Данное изобретение также охватывает фрагменты нуклеиновых кислот, кодирующие модифицированный IL5, а также векторы, несущие указанные фрагменты нуклеиновых кислот, и клетки-хозяева и линии клеток, трансформированные данными векторами. Изобретение также представляет способ идентификации аналогов IL5, которые пригодны в способе согласно изобретению, а также композиции, включающие в себя модифицированный IL5 или содержащие нуклеиновые кислоты, кодирующие аналоги IL5. Предпочтительный вариант данного изобретения предусматривает использование вариантов IL5, в которые введены чужеродные Т-хелперные эпитопы так, чтобы индуцировать продукцию перекрестно реагирующих антител, способных связывать аутологичный IL5.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200101125A 1999-04-23 2000-04-19 Способ понижающей регуляции активности il5 EA200101125A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900552 1999-04-23
US13281199P 1999-05-06 1999-05-06
PCT/DK2000/000205 WO2000065058A1 (en) 1999-04-23 2000-04-19 Method for down-regulating il5 activity

Publications (1)

Publication Number Publication Date
EA200101125A1 true EA200101125A1 (ru) 2002-04-25

Family

ID=26064209

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101125A EA200101125A1 (ru) 1999-04-23 2000-04-19 Способ понижающей регуляции активности il5

Country Status (19)

Country Link
US (2) US7285273B1 (ru)
EP (1) EP1173573A1 (ru)
JP (1) JP2002543098A (ru)
KR (1) KR20020084841A (ru)
CN (1) CN1355846A (ru)
AU (1) AU777952B2 (ru)
CA (1) CA2370391A1 (ru)
CZ (1) CZ20013709A3 (ru)
EA (1) EA200101125A1 (ru)
EE (1) EE200100552A (ru)
HR (1) HRP20010824A2 (ru)
HU (1) HUP0200958A3 (ru)
IL (1) IL145786A0 (ru)
MX (1) MXPA01010625A (ru)
NO (1) NO20015021L (ru)
PL (1) PL351986A1 (ru)
SK (1) SK14832001A3 (ru)
TR (1) TR200103046T2 (ru)
WO (1) WO2000065058A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
RU2319503C2 (ru) * 2001-11-07 2008-03-20 Цитос Байотекнолоджи Аг Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний
BR0213950A (pt) * 2001-11-07 2004-08-24 Cytos Biotechnology Ag Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
WO2003042244A2 (en) * 2001-11-16 2003-05-22 Pharmexa A/S Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
US20060147417A1 (en) * 2002-08-30 2006-07-06 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
US20060292115A1 (en) * 2003-03-24 2006-12-28 Drivas Dimitrios T Methods and compositions for treating and preventing inflammatory conditions
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
PL2958937T3 (pl) * 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
AU2014249150B2 (en) * 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules
CN113214394B (zh) * 2020-10-30 2023-01-06 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5616488A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
JPH09510975A (ja) * 1994-03-28 1997-11-04 ユナイテッド・バイオメディカル・インコーポレイテッド アレルギー治療用合成ペプチドベース免疫原
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
JP3872813B2 (ja) * 1994-05-18 2007-01-24 エス．ピー．アイ． シンセティック ペプチデス インコーポレイテッド ヘテロダイマーポリペプチド免疫原キャリア組成物および方法
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
WO1997000321A1 (en) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
EP1837017A3 (en) 1997-01-22 2009-12-23 Eisai Inc. Microparticles for delivery of nucleic acid
WO1998047923A1 (en) 1997-04-18 1998-10-29 Tanox Biosystems, Inc. Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases
DE69918146T2 (de) * 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung

Also Published As

Publication number Publication date
HRP20010824A2 (en) 2002-12-31
US6746669B1 (en) 2004-06-08
WO2000065058A1 (en) 2000-11-02
AU4100800A (en) 2000-11-10
EP1173573A1 (en) 2002-01-23
CA2370391A1 (en) 2000-11-02
HUP0200958A2 (en) 2002-06-29
NO20015021D0 (no) 2001-10-15
CZ20013709A3 (cs) 2002-11-13
US7285273B1 (en) 2007-10-23
CN1355846A (zh) 2002-06-26
AU777952B2 (en) 2004-11-04
KR20020084841A (ko) 2002-11-11
EE200100552A (et) 2002-12-16
SK14832001A3 (sk) 2003-02-04
HUP0200958A3 (en) 2004-11-29
PL351986A1 (en) 2003-07-14
JP2002543098A (ja) 2002-12-17
NO20015021L (no) 2001-12-21
IL145786A0 (en) 2002-07-25
MXPA01010625A (es) 2003-09-04
TR200103046T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
EA200101125A1 (ru) Способ понижающей регуляции активности il5
NO2017038I2 (no) Adalimumab - Forlenget SPC
WO2002031134A3 (en) Novel serine protease genes related to dppiv
RU2009111266A (ru) Синтез жирных кислот
MA31077B1 (fr) Polypeptides heterologues il-17a/f et utilisation des polypeptides a des fins therapeutiques
CA2330549A1 (en) Diacylglycerol o-acyltransferase
EE200100149A (et) Meetod osteoprotegeriini ligandi (OPGL) in vivo toime mahasurumiseks loomorganismil, OPGL analoog, seda sisaldav immunogeenne kompositsioon ning meetod selle valmistamiseks
DE69737996D1 (de) Methoden zur herstellung von nukleotidintegrasen
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
EA200400688A1 (ru) Иммуногенные миметики мультимерных белков с нерегулярными вставками т-клеточных эпитопов
BE1002375A3 (fr) Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie.
Hwang et al. Immunomic screening of cell surface molecules on undifferentiated human dental pulp stem cells
ATE302214T1 (de) Enamel-matrix bezogene polypeptide
Hülsmann et al. Cardiac lipoprotein lipase: effects of lipopolysaccharide and tumor necrosis factor
WO1990005181A1 (de) REINIGUNG VON Cu/Zn-SUPEROXIDDISMUTASE
WO1998024887A3 (en) Parasitic nematode transglutaminase proteins, nucleic acid molecules, and uses thereof
DE69535091D1 (en) Humane prostacyclinsynthase
Leung et al. Production of specific antigens from Trichinella spiralis using a continuous elution method and isoelectric focusing
KATO et al. Properties of Purified Coichicine-Binding Protein from a Cultured Carrot Cell Extract
EA200000709A1 (ru) Бета-липотропин и его применения
WO1998018942A3 (en) Novel human rab proteins
EP1558735A4 (en) PROMOTER OF PORK UROPLAKINE II AND METHOD FOR PRODUCING USEFUL PROTEINS USING THE PROMOTER
RU2590704C2 (ru) ГЕН PDGF-Bopt ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА ЧЕЛОВЕКА
CN104232585B (zh) 一种携带人金属硫蛋白基因的脐带间充质干细胞及其应用
CA2335335A1 (en) Human erythrocyte differentiation related factor